Progression-Free Survival: Meaningful or Simply Measurable?Christopher M. Booth, Elizabeth A. Eisenhauer|Journal of Clinical Oncology|2012Cited by 320
Evolution of the Randomized Clinical Trial in the Era of Precision OncologyJoseph C. Del Paggio, Christopher M. Booth, John Berry et al.|JAMA Oncology|2021Cited by 200
Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)Christopher M. Booth, Elizabeth A. Eisenhauer, Marinus W. Lobbezoo et al.|European Journal of Cancer|2007Cited by 109
Common Sense Oncology: outcomes that matterChristopher M. Booth, Bishal Gyawali, Manju Sengar et al.|The Lancet Oncology|2023Cited by 101